As technology becomes more commonplace in dermatological practice, it is essential to continuously review the accuracy of teledermatology devices and services compared with in-person care. The last systematic review was conducted over 5 years ago.
As rates of skin cancers increase, there is greater pressure on the dermatology workforce in both rural and urban areas. Different forms of teledermatology have been explored as a solution to this growing problem. 2, 3 The 2 most common types of teledermatology are: store and forward (SAF), involving transfer of images and clinical information to a dermatologist for review at another time and location; and live interactive (LI), usually videoconferencing, which allows real-time interaction between the clinician and patient.
Before implementing a new mode of medical care like teledermatology, it is important to ensure that the diagnostic accuracy is comparable to that of face-to-face (FTF) consultations, and that patient care is not compromised. For the diagnosis of skin lesions, this is not straightforward. When a biopsy is taken the reference standard is the histopathologic result but when the lesion is considered benign, the clinical diagnosis by the dermatologist is accepted as the reference standard. In 2010, a US study of histopathology discordance in melanoma diagnosis reported discordant results in 392 (14.3%) cases. 4 An earlier review of diagnostic accuracy in nonmelanoma skin cancers reported discordant histopathologic results (studies included 2-77 pathologists) in 2% to 7% of cases. 5 These discrepancies in the "reference standard" have implications for studies of diagnostic accuracy and can also have clinical consequences for patients. [4] [5] [6] While histopathology is still the most accurate diagnostic method for skin cancers and remains the gold standard, it is important to take this margin of diagnostic discordance into account when setting thresholds for acceptable levels of diagnostic accuracy for new diagnostic tests.
A systematic review 7 published in 2011 found that the accuracy of FTF dermatology was better than SAF teledermatology for diagnosing skin conditions (weighted mean difference, 11% for primary, 19% for aggregated diagnostic accuracy). However, the authors concluded the levels of diagnostic accuracy and concordance of both SAF and LI teledermatology were still acceptable compared with FTF dermatology. 7 Since that time, there has been significant growth in the number of devices, software, and systems marketed for use by dermatologists, ranging from small dermoscopic attachments for mobile phones and digital cameras and associated mobile applications, to 3-dimensional imaging systems for high resolution full body photography. These technologies have the potential to improve access to specialist services, enable earlier diagnosis of skin cancers, and provide consumers and clinicians with a way of storing high-quality images of lesions to support monitoring of any changes over time.
Five years on, this review is an updated synthesis and critique of the most recent studies of the use of teledermatology specifically for the diagnosis and management of skin cancer. We conducted a review of all studies published since June 2009 (cut-off date for inclusion in the previous review) addressing the following research questions: (1) How accurate is teledermatology for skin cancer diagnosis compared to usual care (FTF diagnosis)? (2) Does teledermatology save clinician and/or patient time, compared with usual care? (3) Are there barriers to adoption of teledermatology in clinical practice for the diagnosis of skin cancer?
Methods
The protocol was registered on PROSPERO International prospective register of systematic reviews and can be accessed at http: //www.crd.york.ac.uk/PROSPERO/display_record.asp?ID =CRD42015014295. The review adheres to the principles of the PRISMA Statement. The PRISMA checklist and inclusion criteria flow chart are included in the Supplement. 8 
Search Strategy
We searched Cochrane, PubMed, Medline, Science Direct, Embase, and Web of Science databases for systematic reviews and original research articles, restricted to human research published in English.
The search terms remote consult, remote consultation, electronic mail, telecommunications, telemedicine, teledermatology, dermatology, store and forward, dermoscopy, teledermoscopy, teledermatoscopy, skin cancer, melanoma, carcinoma, were combined using the appropriate methods for each database.
Study Selection
Studies were included if the primary focus was on the use of teledermatology or teledermoscopy interventions for diagnosing or managing melanoma or nonmelanoma skin cancers. Only full articles were included. Specific exclusion criteria included studies of teledermatology applications using image analysis software, case studies and case series, and studies including participants younger than 18 years. high, or unclear, and the applicability to the original review question is assessed. 9 Applicability to the review question is considered an important aspect of the quality assessment process; it is possible that even high-quality, well-designed and reported studies with low risk of bias, differ from the review question in some fundamental way that reduces the generalizability of results.
Results of the quality assessment process are presented in Table 1 .
Data Synthesis
Two researchers (A.F. and K.D.) extracted data. The outcomes related to each review question are defined below:
(1) How accurate is teledermatology for skin cancer diagnosis compared with usual care (FTF diagnosis)?
The main outcomes of diagnostic accuracy, diagnostic concordance, management accuracy and management concordance are defined in Table 2 , specifying the relevant reference standard (current gold standard) and index test (comparator). Studies of diagnostic accuracy were separated into teledermatology and teledermoscopy subgroups.
(2) Does teledermatology save clinician and/or patient time, compared with usual care?
Results relating to any aspects of clinician or patient time were extracted. This included time in days between referral and specialist consultation, time in days between referral and surgical excision of the lesions, and Breslow thickness as a proxy measure of delayed diagnosis.
(3) What are the enablers and barriers to adoption of teledermatology in clinical practice, for the diagnosis of skin cancer?
Results from all studies that explored aspects of patient and clinician satisfaction and receptivity, feasibility of teledermatology, or barriers to implementation were synthesized.
Results
The study selection process is detailed in the eFigure in the Supplement. Results from all database searches were combined and duplicates were removed. Titles and abstracts were reviewed and 153 of 241 studies were excluded for the following reasons: teledermatology for diagnosing or managing skin cancer was not a primary focus; study published prior to June 2009; conference abstract only, or full text not available in English. Of 88 full-text articles assessed, 41 were excluded owing to criteria defined above, and 25 were published prior to June 2009. Twenty-eight articles met inclusion criteria but 7 of 28 were excluded owing to insufficient reporting of methods to enable quality assessment. [19] [20] [21] [22] [23] [24] [25] Characteristics of the 21 included studies are presented in Table 3 .
Diagnostic Accuracy
Eight studies (7 including dermoscopy) reported the diagnostic accuracy of teledermatology consultations 10, 11, 17, 18, 26, 27, 35, 36 (Table 4) . Three of the 8 studies also assessed accuracy of FTF diagnosis compared with histopathological diagnosis, and compared the level of accuracy for FTF diagnoses with teledermatology diagnoses. 11, 17, 35 Three studies assessing diagnostic accuracy of teledermatology using 133 to 188 clinical images (without dermoscopy) reported 68% to 85% agreement between teledermatology 11, 27 and sensitivity and specificity for detecting melanoma of 98% and 30%, respectively. 18 Five studies including dermoscopic or microscopic images of 69 to 613 lesions in teledermatology consultations reported agreement between 51% to 92% 11, 27, 35 (κ, 0.41-0.63), 17 and sensitivity and specificity for detecting melanoma of 96% and 62%, respectively. 10 One study reported very high sensitivity and specificity of teledermatology for both malignant melanocytic lesions (sensitivity, 100%; specificity, 97%-98%; n = 6) and malignant nonmelanocytic lesions (sensitivity, 97%; specificity, 92%-94%, n = 58), for both clinical and dermoscopic images (no significant differences between these methods).
11
Studies that compared the diagnostic accuracy of teledermatology with FTF diagnoses reported variable results. Levels of agreement between teledermatology diagnoses and histopathological diagnoses were comparable to levels of agreement between FTF diagnoses and histopathological diagnoses in 1 study; 79% to 85% for teledermatology (clinical images, 79%; dermoscopic images, 85%) and 85% for FTF. 11 However, in a second study that compared teledermatology and FTF primary diagnoses as well as malignant and/or benign categorization, the agreement was lower for teledermatology (51%-61% for TD vs 67% FTF for primary diagnoses, and 75%-80% for teledermatology and 87% FTF for benign vs malignant). 35 A third study reported much lower agreement between telediagnosis and histopathological diagnosis, compared with FTF diagnosis and histopathological diagnosis (κ, 0.41-0.63 for TD, κ, 0.90 for FTF).
17
Four other studies reported diagnostic accuracy of teledermatology, without any comparison with FTF diagnoses. These studies reported agreement between telediagnosis and the reference standard of 51% to 100%. 10, 26, 27, 36 When separating malignant and benign lesions, telediagnoses of malignant lesions were histopathologically confirmed in 62% to 100% of cases, depending on the study. Of note, the study reporting 100% agreement between telediagnosis and histopathological diagnosis for malignant lesions only included 8 malignant lesions. 26 
Diagnostic Concordance
Ten included studies reported diagnostic concordance between teledermatology and FTF clinical diagnoses (Table 4) . These results were not histologically confirmed, so the FTF diagnosis is considered the reference standard.
Three studies without dermoscopy reported diagnostic concordance between 62% and 94%. Diagnostic concordance in studies including dermoscopic images ranged from 46% to 90% for primary diagnoses, or 71% to 91% for aggregated diagnostic categories. There were significant differences in diagnostic concordance between teledermatology and FTF clinical diagnoses when the same dermatologist performed both methods (κ, 0.95; range, 0.91-0.99) 16 compared with studies involving different dermatologists (κ, 0.47-0.51).
35
Of note, 1 study examined interobserver reliability between 5 teledermatologists and reported wide variation in levels of agreement (κ, 0.38-0.97). Copyright 2017 American Medical Association. All rights reserved.
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Quality of Diagnostic Accuracy and Diagnostic Concordance Studies
Most studies of diagnostic accuracy and concordance of teledermatology had significant methodological limitations. Many studies did not take (or report) adequate steps to reduce risk of selection bias, which could lead to overestimating the diagnostic accuracy ( Table 5) .
For example, enrolling high-risk patients or excluding low-quality images could lead to apparent higher sensitivity of teledermatology than would be found in a general population group. Abbreviations: FTF, face to face; MM, malignant melanoma; TD, teledermatologist. Other concerns with increased risk of bias included studies where the same dermatologist provided the FTF and telediagnosis; this may bias the index test if the telediagnosis was provided following the FTF diagnosis, or the reference standard, if vice versa (Table 5) .
There were no systematic differences between the results of studies that seemed to have taken steps to reduce risk of bias, compared with those with higher risk of bias. For example, there were higher-quality studies that reported both higher and lower levels of diagnostic accuracy, and the same was true of studies with significant limitations. This suggests the wide variation in results of diagnostic accuracy and concordance is not owing to 1 consistent identifiable type of bias, but rather is a owing to a combination of methodological limitations in most studies in this field. These may be actual limitations, or important aspects of study design omitted in the reporting of studies, as evidenced by the large number of unclear ratings ( Table 1) .
Accuracy of Clinical Management Plans
Only 2 recent studies 35,36 assessed the treatment accuracy of teledermatology, 35,36 measured by the level of agreement between recommended treatment based on teledermatological diagnosis and histopathological diagnosis (Table 4) . In 1 study, 35 1 melanoma in situ (1.5%, n = 69) would have received no treatment based on the telediagnosis from one of the dermatologists in the study. The second dermatologist in that study made adequate treatment decisions in 100% of cases. The second study used teledermatology as a triage tool. All 19 patients with invasive melanoma and all 16 patients with melanoma in situ were prioritized appropriately as high, and at least medium priority, respectively. In the same study, 3 of 4 patients with invasive melanomas and 3 of 5 patients with melanoma in situ referred by traditional paper referral were incorrectly given medium or low priority, and low priority, respectively.
Concordance of Clinical Management Plans
Six studies (3 with dermoscopy and 3 without) examined treatment concordance between teledermatology and FTF consultations (Table 4) . Agreement between management plans (ie, decision to excise lesions, review in short term, long term, or not review at all) ranged from 66% to 85% (κ, 0.19-0.83).
12,14,17,27,29,37
Time Involved in Teledermatology Consultations Breslow Thickness
One study including 201 participants reported Breslow thickness of melanoma as an indicator of earlier diagnosis and reported lower Breslow thickness in the teledermatology group compared with conventional referral (1.06 mm vs 1.64 mm, P = .03).
38

Waiting Time
Four studies examined the effect of teledermatology consultations on waiting times to FTF appointments, waiting time to diagnosis, and/or waiting time to surgery. Reductions in waiting times in teledermatology groups were reported in all studies.
Three studies 10, 31, 36 specifically reporting waiting times for patients with melanoma found patients in teledermatology groups waited significantly shorter periods than those with conventional referrals. The actual average waiting periods varied significantly between studies, from 9 days (teledermatology) compared with 14 days (paper referral), 9 days (teledermatology) vs 26.5 days (FTF clinic), and 36 (photo triage) compared with 39 days (conventional referral). Patients who were referred using teledermatology triage systems more often received primary treatment in a single dermatology appointment and required fewer appointments for treatment.
31,36
Patient Satisfaction and Barriers to Teledermatology
Eleven included studies explored patient satisfaction, clinician factors, and/or a range of barriers to teledermatology. The heterogeneous nature of these studies and the outcome measures allowed only a descriptive summary.
Patient Satisfaction
Four studies examined measures of patient satisfaction, including confidence and use of teledermatology, satisfaction with waiting times, preferences, and willingness to pay.
In 2 of 11 studies a total of 55 (100%) consumers submitted their own images (with and without dermoscopy) and reported they were satisfied with the ease of use 14 and willing to pay out-of-pocket costs for teledermatology services. 32 Economic modeling was used to estimate willingness to pay, 32 suggesting consumers would pay an average of A$110 to have teledermoscopy review as a health service option, in addition to the currently available options of skin selfexamination, skin cancer clinic, or general practitioner clinic. This concept was supported by a US study that reported patients were willing to pay $20 to $500 for a mobile dermatoscope (median, $100).
33
Other benefits of teledermatology and teledermoscopy reported by patients included shorter waiting times, more frequent monitoring, and improved privacy and comfort. One study measuring patient satisfaction using a 5-point satisfaction scale reported higher satisfaction with waiting times (2.9 FTF vs 4.0 teledermatology) and overall satisfaction compared with FTF (3.8 FTF vs 4.5 teledermatology).
30
Diagnostic Difficulty and Diagnostic Confidence
One study 35 reported higher diagnostic difficulty for teledermatology consultations vs FTF consultations. Clinicians using teledermatology reported 61% to 87% cases as high difficulty compared with the clinician seeing patients FTF, who reported 54% as highdifficulty diagnoses. Another study examining diagnostic confidence of clinicians found diagnostic agreement increased as the clinicians diagnostic confidence increased.
29
Image Quality Studies 14,15,17 reported up to 8% of images as being unevaluable or unacceptable quality, but this proportion increased to 36% bad quality images when clinicians were asked to rate image quality as good, reasonable, or poor. Of note, a large study 26 of 959 images found telediagnosis was possible in 99.7% of cases, and only 1% of dermoscopic and 4% of clinical images were rated as low quality.
Interobserver Reliability
Only 1 included study 16 reported the interobserver reliability of teledermatologists as moderate for diagnostic group (κ, 0.56-0.78) and low for management plans (κ, 0.31-0.38).
Self-monitoring
An Australian study of 49 participants examining the introduction of mobile dermoscopy into current skin self-examination recom-mendations reported barriers to effective self-monitoring. 13 In this study, the FTF dermatologist identified 40 lesions of concern on 25 people, which had not been identified during skin selfexamination. Of these 40 lesions, 24 did not meet the asymmetry and color rule communicated to consumers as a method for identifying concerning lesions. However, none of these lesions were subsequently diagnosed as melanoma.
Discussion
Five years after the last systematic review of teledermatology for the diagnosis and treatment of skin conditions, including skin cancer, 7 the conclusion remains the same; the accuracy of FTF dermatology consultation is generally higher than teledermatology. However, some studies in this review did report high accuracy of teledermatology diagnoses for skin cancer. Addressing the limitations of previous research will help to determine whether teledermoscopy is a safe and appropriate alternative to in-person assessment, which is particularly important for countries with high rates of skin cancers and geographically dispersed populations, including Australia and the United States.
Future researchers in this field should aim to overcome the methodological limitations including lack of histopathology as reference standard, sample and diagnostic bias. A crossover trial of teledermatology and FTF diagnosis could be beneficial, with different clinicians providing the teledermatology and FTF diagnosis, before switching into the other arm. Carefully designed and rigorous diagnostic studies could help to identify whether teledermatology is equally or more accurate for diagnosing particular types of lesions, and whether the variation seen in accuracy of teledermatology is owing to differences in clinical opinions, or some aspect of the teledermatology technology or process itself. Additional recommendations based on this review are presented in Table 5 .
A common challenge in studies of telemedicine interventions is separating the effect of the intervention from other factors influencing the clinical outcomes. The most methodologically sound way to test the diagnostic accuracy of teledermatology would be assigning different clinicians for the teleconsultations and FTF consultations, to prevent bias resulting from recall of the lesions and associated diagnosis the second time they see them. However, it is necessary to first ensure the clinicians have high inter-rater reliability, which may be more likely when clinicians have had similar training and are equally as experienced as dermatologists. Without this, it is very difficult to tell whether the limited agreement in diagnoses is related to the use of the technology itself, or differences in clinical opinion which could ordinarily exist in practice, as suggested by the variation in interobserver reliability reported in studies 16, 17 comparing diagnoses and management plans from multiple dermatologists and previous studies in dermatopathology. [4] [5] [6] The nomenclature used by clinicians and researchers can influence measures of accuracy. This has been recognized and is currently being addressed by the International Skin Imaging Collaboration. 40 This aside, even dermatologists in the same countries who have received different training may describe the same lesion differently. If the researchers are not well versed in dermatology terminology, this variation in nomenclature could inadvertently result in underestimation of diagnostic accuracy.
While diagnostic accuracy is important, its relevance is lessened as long as the patient receives the same treatment, for example if the lesion is recommended for excision regardless. Studies included in this review focusing on agreement between prescribed management plans from teleconsultations vs FTF consultations suggest the management plans prescribed by teledermatologists were appropriate, and only 1 missed case of melanoma in situ was reported in 1 study. 35 Unfortunately all studies had small sample sizes, requiring confirmation in larger and more diverse samples. Importantly, when teledermatology was used as a triage tool, all melanoma and melanoma in situ cases were correctly prioritized as high priority, while a number of melanoma and melanoma in situ were inappropriately triaged as medium or low priority using conventional (nonteledermatology) referral pathways.
Very few studies (4 of 21) assessed health services outcomes measures. 10, 31, 36, 38 Those that did found the use of teledermatology could reduce waiting times and result in earlier assessment and treatment, patients reported high satisfaction and were willing to pay out of pocket for access to such services. On the other hand, clinicians reported higher diagnostic difficulty for teledermatology cases compared with FTF consultations and levels of diagnostic agreement were found to be related to clinician-reported diagnostic confidence. It is possible that with more experience and exposure to teledermatology cases, clinicians' increased confidence with this mode of health care delivery could result in improved accuracy. There were no studies assessing longer-term outcomes like quality of life or workflow that were specific to skin cancer and eligible for inclusion in this review.
Authors of a recent commentary 41 from Spain proposed teledermatology be used primarily to improve referral and triage systems, rather than replacing in-person consultations, owing to the current lack of high-level evidence to support diagnostic accuracy of teledermatology. The evidence from this review also supports the implementation of teledermatology as a referral and/or triage tool. However, the potential benefits to patients who currently have limited access to dermatological care suggests there is reason to invest more resources to definitively establish the diagnostic accuracy of teledermoscopy for skin cancer diagnosis.
Conclusions
Incorporating economic outcome measures into a larger diagnostic study would enable concurrent exploration of the most suitable models of care to integrate teledermatology into the diagnosis and treatment of patients with melanoma and nonmelanoma skin cancers. As staples of the histopathology laboratory, hematoxylin and eosin have become the inimitable scaffold on which many of our dermatological diagnoses are made. Hematoxylin (etymologically derived from the Greek hematos: blood and xylos: tree) was originally derived from the heartwood (logwood) of the tree Hematoxylon campechianum, whose roots and trunk exude a ruddy turbid colorant when boiled or steamed.
1,2 The product was discovered by Spanish explorers in the Yucatan Peninsula (in modern Mexico) in the 16th century. The indigenous Maya had long used it to dye cotton and to halt diarrhea.
Logwood was soon exported to Europe by the Spanish for use as a textile colorant, attracting attention and envy, and it soon became a target of piracy, with English, French, and Dutch forces all seeking to profit from its use. Its value was such that Spain initially claimed a monopoly on all logwood sales and later the right to profit from logwood plantations was part of the political settlement that followed the Seven Years' War between Britain, France, and Spain (1754-1763).
Hematoxylin was originally used as a fabric dye and was used to stain the uniforms of soldiers in the American Civil War and subsequently the First and Second World Wars. Its use as a dye underwent a renaissance during the Second World War as allied forces sought sources of dye other than German-manufactured aniline dyes. Furthermore, it has been used as a paint in artwork.
Owing to its short-lived "fugitive" colorant effect, logwood was initially outlawed in England during the Elizabethan era. Later, adding a mordant derived from a heavy metal (eg, aluminum, iron, or tungsten) to make the color more permanent became an established practice. It is the mordant that increases the hematein's (the basic dye extract) affinity for nucleic acids and also defines the staining characteristics of the hematoxylins used in pathology to this day. Thus, hematoxylins are often classified according to the mordants they contain, and examples include aluminum hematoxylins (Ehrlich, Delafield, Mayer, Harris, Gill), iron hematoxylins (Heidenhain, Weigert, Verhoeff), and tungsten hematoxylins (phosphotungsten acid hematoxylin) to name but a few.
In 1879, Cook published one of the first protocols describing hematoxylin extraction for use in staining tissue, using an alum-copper extraction process. 3 Despite the advent of synthetic dyes, the use of hematoxylin for staining tissue has endured to the present, albeit with a lower threat of piracy and use as a political bargaining tool.
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